Mode
Text Size
Log in / Sign up
N/A N=29 Randomized Double-blind Treatment

Cochlear Implant With Dexamethasone Eluting Electrode Array

Sensorineural Hearing Loss · Bilateral Hearing Loss

Enrolled (actual)
29
Serious AEs
17.2%
Results posted
Apr 2025
Primary outcome: Primary: Comparison of Monopolar (MP1+2) Impedance Measurement (kOhms) Between Randomization Groups at 6 Months Postoperative — 3.99; 8.66 kOhms

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CI632D (Device); CI632 (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cochlear
Primary completion
Jul 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Comparison of Monopolar (MP1+2) Impedance Measurement (kOhms) Between Randomization Groups at 6 Months Postoperative
3.99; 8.66
PRIMARY
Change in Speech Perception Performance (Pre-recorded CNC Words in Quiet in Sound Booth Testing) Compared to Pre-operative Baseline Measured at 6 Months Postoperative With CI632D
39.5
SECONDARY
Comparison of Rate and Type of Device Related Adverse Events Between Randomization Groups
2; 3; 12; 12; 8; 5
SECONDARY
Comparison of Speech Perception Performance (Pre-recorded CNC Words in Quiet in Sound Booth Testing) Between the Randomization Groups at Six Months Postoperative
57.8; 68.0
SECONDARY
Comparison of Speech Perception Performance (AzBio Sentences in Quiet in Sound Booth Testing) Between Randomization Groups at Six Months Postoperative
46.1; 55.3

Summary

An evaluation of Cochlear's cochlear implant electrode array which passively elutes dexamethasone for a defined period of time to help reduce inflammatory responses.

Eligibility Criteria

Inclusion Criteria

  • Post-lingual, bilateral, moderate (≥ 40 dB HL) to profound sensorineural hearing loss at 250, 500and 1000 Hz and profound high-frequency hearing loss, defined by a pure-tone average (PTA) threshold, 2000 through 8000 Hz, ≥ 90 dB HL.
  • 18 years or older at time of consent.

Exclusion Criteria

  • Abnormal cochlear and middle ear anatomy
  • History with cochlear implant surgery
  • Allergy to dexamethasone
  • Women who are pregnant or plan to become pregnant
  • Unable/unwilling to comply to study requirements
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04750642). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search